Atypical antipsychotic agents and increased risk of diabetes: Class action or differential action?

Expert Opinion on Drug Safety

Volumn 4, Issue 1, 2005, Pages 55-68

  Ananth, Jambur ^a   Kolli, Smita ^a  

^a UCLA MEDICAL CENTER   (United States)

Author keywords

Atypical antipsychotic (AAP) drugs; Drug induced diabetes; Pathophysiology; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; C PEPTIDE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; HEMOGLOBIN A1C; INSULIN; NEUROLEPTIC AGENT; OLANZAPINE; PHENOTHIAZINE; PLACEBO; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE;

CLINICAL TRIAL; COMPARATIVE STUDY; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DIABETOGENESIS; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG WITHDRAWAL; EARLY DIAGNOSIS; ETHNIC GROUP; EXERCISE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; LIFESTYLE; MALNUTRITION; METABOLIC ACIDOSIS; MORBIDITY; MORTALITY; OBESITY; OVERNUTRITION; PANCREATITIS; PATHOPHYSIOLOGY; PSYCHOSIS; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SEDATION; SMOKING; SYMPTOMATOLOGY; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; DIABETES MELLITUS; HEALTH STATUS; HUMANS; PSYCHOTIC DISORDERS; RISK FACTORS;

EID: 12544257654     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.4.1.55     Document Type: Review

References (148)

1. MOKDAD AH, FORD ES, BOWMAN BA et al.: Diabetes trends in the US 1990-1998. Diabetic Care (2000) 23:1278-1283.
2. WORLD HEALTH ORGANIZATION: Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO Consultation. WHO/NCD/NCS/99.2. Geneva: WHO (1999).
3. AMERICAN DIABETIC ASSOCIATION: Diabetes 2001 Vital Statistics. Alexandria, VA. ADA (2001).
4. KARAVONEN M, PITKANIEMI J, TUOMILEHTO J: The onset age of Type 1 diabetes in Finnish children has become younger. The Finnish Childhood Diabetes Registry Group. Diabetes Care. (1999) 22 1066-1070.
5. JONSSON B: Revealing the cost of Type II diabetes in Europe. Daibetologia (2002) 45:S5-S12.
6. ZIMMET P, SHAW J, ALBERTI KG: Preventing Type 2 diabetes and the dysmetabolic syndrome in the real world: a realistic view. Diabet. Med. (2003) 20:693-702
7. ZIMMET P: Type 2 (non-Insulin-dependent) diabetes and epidemiological overview. Diabetologia (1982) 22:399-411.
8. ANANTH J, GUNATILAKE S, AQUINO S, BACH V, COSTA J: Are African-American patients at a higher risk for olanzapine-induced glucose intolerance? Psychopharmacology (2001) 157(3):324-325.
9. COLDITZ GA, WILLET WC, ROTNITZKY A, MANSON JE: Weight gain as a risk factor for clinical diabetes mellitus in women. Ann. Internal Med. (1995) 122:481-486.
10. HU FE, SIGAL RJ, RICH EDWARDS JW et al.: Walking compared with vigorous physical activity and risk of Type 2 diabetes in women: a prospective study. JAMA (1999) 282:1433-1439.
11. CAREY VJ, WALTERS EE, COLDITZ GA et al.: Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women. The Nurses' Health Study. Am. J. Epidemiol. (1997) 145 614-619.
12. MAISON P, BYRNE CD, HALES CN, DAY NE, WAREHAM NJ: Do different dimensions of metabolic syndrome change together over time? Evidence supporting obesity as the central feature. Diabetes Care (2001) 24:1758-1763.
13. HOLT RI: Diagnosis, epidemiology and pathogenesis of diabetes mellitus: an update for psychiatrists. Br. J. Psychiatry (2004) 184(Suppl. 47):S55-S63.
14. THE EXPERT COMMITTEE ON THE DIAGNOSIS AND CLASSIFICATION OF DIABETES MELLITUS: Report ofthe Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetic Care (2003) 26 Suppl. 1):S5-S20.
15. HARRIS MI: Impaired glucose tolerance in the US population. Diabetes Care (1989) 12:464-474.
16. MEIGS JB, MULLER DC, NATHAN DMBLAKE DR, ANDRES R: The natural history of progression from normal glucose tolerance to Type II diabetes in the Baltimore Longitudinal Study of Aging. Diabetes (2003) 52 1475-1484.
17. ALBERTI KG: The clinical implications of impaired glucose tolerance. Diabet. Med. (1996) 13:927-937.
18. HOENIG M, FERGUSON DC: Diagnostic utility of glycosylated hemoglobin concentrations in the cat. Domest. Anim. Endocrinol. (1999) 16:11-17.
19. DEICHMANN RE, CASTELLO E, HORSWELL R, FRIDAY KE: Improvements in diabetic care as measured by HbA1c after a physician education project. Diabetic Care (1999) 22:1612-1616.
20. SNEHALATHA C, RAMACHANDRAN A, STTYAVANI K, VIJAY V: Limitations of glycosylated hemoglobin as an index of glucose intolerance. Diabetes Res. Clin. Pract. (2000) 47:129-133.
21. GILLERY P, HUE G, BORDAS-FONFREDE M et al.: Hemoglobin A1c determination and hemoglobinopathies: problems and strategies. Ann. Biol. Clin. (2000) 58:425-429
22. DEFRONZO RA: Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes (1988) 37:667-687.
23. KAHN CR: Insulin resistance, insulin insensitivity; and insulin unresponsiveness: a necessary distinction. Metab. Clin. Exp. (1978) 27:1893-1902.
24. DEFRONZO RA, FERRANNINI E: Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care (1991) 14 173-194.
25. MOLLER DE, FLIER JS: Insulin resistance- mechanisms, syndromes, and implications. N. Engl. J. Med. (1991) 325 938-948.
26. REAVEN GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes (1998) 37:1595-1607.
27. FORD ES, GILES WH, DIETZ WH: Prevalence of metabolic syndrome among US adults: findings from the third national health and nutrition examination survey JAMA (2002) 287:356-359.
28. MITRAKOU A. KELLEY D, MOKAN M, VENEMAN T, PANGBURN T, REILLY J: Role of reduction of suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N. Engl. J. Med. (1992) 326:22-29.
29. PRATLEY RE, WEYER C: The role of impaired catty insulin secretion in the pathogenesis of Type II diabetes mellitus. Diabetologia (2001) 44:929-945.
30. UK PROSPECTIVE DIABETIC STUDY GROUP: UK Prospective Diabetic Study 16. Overview of 6 years' therapy of Type II diabetes: a progressive disease. Diabetes (1995) 44:1249-1258.
31. HOLMAN RR. Assessing the potential for alpha-glucosidase inhibitors in prediabetic states. Diabetes Res. Clin. Pract. (1998) 40(Suppl.):S21-S25.
32. BLACK DW, FISHER R: Mortality in DSM III-R schizophrenia (1992) 7:109-116.
33. BROWN S: Excess mortality of schizophrenia: a meta-analysis. Br. J. Psychiatry (1997) 171:502-508.
34. DIXON L, WEIDEN P, DELAHANY J et al.: Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr. Bull. (2000) 26:903-912.
35. BRACELAND FJ, MEDUNA LJ, VAICHULIS JA. Delayed action of in schizophrenia. Am. J. Psychiatry (1945) 102:108-110.
36. FREEMAN H: Resistance to insulin in mentally disturbed soldiers. carbohydrate metabolism to psychotic states. Arch. Neurol. Psychaitr. (1946) 56:74-79.
37. RYAN MC, COLLINS P, THAKORE JH: Impaired fasting glucose tolerance in first episode, drug naïve patients with schizophrenia. Am. J. Psychiatry (2003) 160:284-289.
38. MUKHERJEE S, DECINA P, BROCOLA V, SARACENI F, SCAPICCHIO PL: Diabetes mellitus in schizophrenic patients. Compr. Psychiatry (1996) 37:68-73.
39. HOLT RI, PEVELER RC, BYRNE CD: Schizophrenia, the metabolic syndrome and diabetes. Diabetes Med. (2004) 21:515-523.
40. KOOY FN: Hyperglycemia in mental disorders. Brain (1919) 42:214-289.
41. RAPHAEL T, PARSONS JP: Blood sugar studies in dementia praecox and manic- depressive insanity. Arch. Neurol. Psychiatr. (1921) 5:687-709.
42. LORENZ WF: Sugar tolerance in dementia praecox and other mental states. Arch. Neurol. Psychiatr. (1922) 8:184-196.
43. BARRET TB, SERRE P: Blood analysis and sugar tolerance in mental disease. J. Nerv. Ment. Dis. (1924) 59:561-570.
44. HENRY GW, MANGAN E: Blood in personality disorders. Arch. Neurol. Psychiatr. (1925) 13:743-749.
45. KASANIN J: The blood sugar curve in mental disease. II. The schizophrenia (dementia praecox) groups. Arch. Neurol. Psychiatr. (1926) 16:414-419.
46. FREEMAN H, RODNICK EH, SHAKOW D et al.: The carbohydrate tolerance of mentally disturbed soldiers. Psychosom. Med. (1944) 6:311-317.
47. LAMBERTI JS, CRILLY J, MAHARAJ K, OLSON D, COSTEA O: Prevalence of adult-onset diabetes among outpatients receiving antipsychotic drugs. Schizophr. Res. (2003) 60(Suppl.):360.
48. LAMBERTI JS, CRILLY J, MAHARAJ K et al.: Prevalence of diabetes mellitus among outpatients with severe mental disorders receiving atypical antipsychotic drugs. J. Clin. Psychiatry (2004) 65:702-706.
49. MUKHERJEE S, SCHNUR DB, REDDY R: Family history of Type II diabetes in schizophrenic patients. Lancet (1989) 1 8636):495.
50. ADAMS PF, MARANO MA: Current estimates from the national Health interview survey 1994: vital and health statistics series 10, number 193, DHS Publication (1995) PJS 96-1521. Hyattsville MD National Center for Health statistics.
51. DYNES JB: Diabetes in schizophrenia and diabetes in nonpsychotic medical patients. Dis. Nerv. Syst. (1969) 30 34-344.
52. CHETA D, DUMITRESCU C, GEOGESCOU M, COCIOABA G, LICHIARDOPOL R, STAMORAN M: A study on the types of diabetes mellitus in first degree relatives of diabetic patients. Diabetes Metab. (1990) 16 11-15.
53. SHILOAH E, WITZ S, ABRAMOVITCH Y, COHEN O, WEISS M, UNGER A: Effect of psychotic stress in non diabetic subjects on beta cell function and insulin sensitivity. Diabetes Care (2003) 26:1462-1467.
54. SCHWARTZ L, MUNOZ R: Blood sugar levels in patients treated with chlorpromazine. Am. J. Psychiatry (1968) 125:253-255.
55. MCKEE HA, D'ARCY PE, WILSON PJ: Diabetes in schizophrenia: a preliminary study. J. Clin. Hosp. Pharmacy (1986) 11:297-299.
56. LILLIKER SL: Prevalence of diabetes in manic depressive population. Compr. Psychiatry (1980) 21:270-275.
57. LEAN ME: Obesity: burdens of illness and strategies for prevention or management. Drugs Today (2000) 36:773-784.
58. HERRAN A, DE SANTIAGO A, SANDOYA M, FERNANDEZ MJ, DIEZ-MAURIQUE JF, VASQUEZ-BARQUERO JL: Determinants of smoking behavior in our patients with schizophrenia. Schizophr. Res. (2000) 41 373-381.
59. JESTE DV, GLADSJO JA, LINDAMER LA: Medical comorbidity in schizophrenia. Schizophr. Bull. (1996) 22:413-430.
60. CHARATAN FB, BARLETT NG: The effect of chlorpromazine on glucose tolerance. J. Ment. Sci. (1955) 101:351-353.
61. HILES BW: Hyperglycemia and glucosuria fllowing chlorpromazine therapy (letter). JAMA (1956) 162:1651.
62. MORAZEWSKI AS, DU BUOIS KP: The influence of chlorpromazine on intermediary carbohydrate metabolism. Arch. Int. Pharmacodyn. (1959) 120(2):201-221.
63. KORENYI C, LOWENSTEIN B: Chlorpromazine induced diabetes. Dis. Ner. Syst. (1968) 29(12):827-828.
64. AMDISEN A: Diabetes mellitus as a side effect of treatment with tricyclic neuroleptic. Acta Psychiatr. Scand. (1964) 4 411-414.
65. THONNARD NEUMANN E: Phenothiazines and diabetes in hospitalized women. Am. J. Psychiatry (1968) 124:138-142.
66. KESKINER A, EL-TOUMI A, BOUSQUET T: Pychotropic drugs, diabetes and chronic mental patient. Psychosomatics (1973) 14 176-181.
67. SUBRAMANIAM M, CHONG SA, PEK E: Diabetes mellitus and impaired glucose tolerance in patients with schizophrentia. Canad. J. Psychiatry (2003) 48:345-347.
68. DOMON SE, WEBBER JC: Hyperglycemia secondary to olanzapine. J. Child Adolesc. Psychopharmacol. (2002) 11:285-288.
69. MELKERSSON KI, DAHL ML: Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses. Psychopharmacology (2003) 170:157-166.
70. JIN H, MEYER JM, JESTE DV: Phenomenology and risk factors for new onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann. Clin. Psychiatry (2002) 22:11-19
71. ANANTH J, VENKATESH R, BURGOYNE K, SARATH G: Atypical antipsychotic drug use and diabetes. Psychother Psychosom. (2002) 71:244-254.
72. KOVAL MS, RAMES T, SCHWARKOPF SB: Diabetic keroacidosis as a side effect of clozapine: a case report. Am. J. Psychiatry (1994) 151:1520-1521.
73. POPLI AP, KONICKI PE, JURJUS GJ, FULLER MA, JASKIW GE: Clozapine and associated diabetes mellitus. J. Clin. Psychiatry (1997) 58:108-111.
74. COLLI A, COCCIOLO M, FRANCOBANDIERA F, ROGANTIN F, CATTALINI N: Diabetic ketoacidosis associated with clozapine treatment. Diabetes Care (1999) 22:176-177.
75. PIERIDES M: Clozapine monotherapy and ketoacidosis. Br. J. Psychiatry (1997) 171:90-91.
76. BRUGMAN NJ, COHEN D, DE VRIES RH: Diabetes mellitus after treatment with clozapine. Ned. Tijdschr. Geneeskd. (2000) 144 437-439.
77. VON HAYEK DV, HUTTL V, REISS J, SCHWEIGER ND, FUESSL HS: Hyperglycemia and ketoacidosis associated with olanzapine. Nervenarzt. (1999) 70:836-837.
78. KOLLER EA, SCHNEIDER B, BENNETT K, DUBITSKY G: Clozapine-associated diabetes. Am. J. Med. (2001) 3:716-723.
79. KOLLER EA, DORAISWAMY PM: Olanvapine-associated diabetes mellitus. Pharmacotherapy (2002) 22:841-852.
80. KOLLER EA, CROSS JT, DORAISWAMY PM, MALOZOWSKI SN: Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy (2003) 23:735-744
81. KOLLER EA, WEBER J, DORAISWAMY PM, SCHNEIDER BS: A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J. Clin. Psychiatry (2004) 65:857-863.
82. CROARKIN PE, JACOBS KM, BAIN BK: Diabetic ketoacidosis associated with risperidone treatment. Psychosomatics (2000) 41 369-370.
83. HAUPT DW, NEWCOMER JW: Risperidone-associated diabetic ketoacidosis [letter]. J. Psychosomatics (2001) 42:279-280.
84. MALLYA A, CHAWLA P, BOYER SK, DEROSEAR L: Resolution of hyperglycemia on risperidone discontinuation: a case report [letter]. J. Clin. Psychiatry (2002) 63:453-454.
85. ANANTH J, JOHNSON KM, LEVANDER EM, HARRY JL: Diabetic ketoacidosis, neuroleptic malignant syndrome, and myocardial infarction in a patient taking risperidone and lithium carbonate. J. Clin. Psychiatry (2004) 65(5):724.
86. WIRSHING DA PIERRE JM, EYLER J, WEINBACH J, WIRSHING WC: Risperidone-associated new onset of diabetes. Biol. Psychiatry (2001) 50:148-149.
87. DOMON SE, CARGILLE CS: Quetiapine-associated hyperglycemia and hypertriglyceridemia. J. Am. Acad. Child Adolesc. Psychiatry (2002) 41:495-496.
88. SOBEL M, JAGGERS ED, FRANZ MA: New-onset diabetes associated with the initiation of quetiapine treatment. J. Clin. Psychiatry (1999) 60:556-557.
89. PROCYSHYN RM, PANDE S, TSE G: New- onset diabetes mellitus associated with quetiapine. Can. J. Psychiatry (2000) 45 7):668-669.
90. PFIZER: Data on file (2000).
91. WIRSHING DA, SPELLBERG BJ, ERHART SM, MARDER SR, WIRSHING WC: Novel antipsychotics and new onset diabetes. Biol. Psychiatry (1998) 44:778-783.
92. AVRAM AM, PATEL V, TAYLOR HC, KIRWAN JP, KALHAN S: Euglycemic clamp study in clozapine-induced diabetic ketoacidosis. Ann. Pharmacother. (2001) 35:1381-1387.
93. HENDERSON D, CALGIERO E, GRAY C, NASRALLAH RA, HEYDEN DL, SCHONFELD DA: Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five year naturalistic study. Am. J. Psychiatry (2000) 157:975-981.
94. HAGG S, JOELSSON IM, JORNDAL T, SPIGHT O, OJA G, DAHLQVIST R: Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J. Clin. Psychiatry (1998) 59 294-299.
95. MELKERSSON KI, HULTING A-L, BRISMAR KE: Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. J. Clin. Psychiatry (1999) 60:783-791.
96. CHAE B-J, KANG B-J: The effect of clozapine on blood glucose metabolism. Hum. Psychopharmacol. Clin. Exp. (2001) 16 265-271.
97. SERNYAK MJ, GULANSKI B, LESLIE DL, ROSENHECK R: Undiagnosed hyperglycemia in clozapine-treated patients with schizophrenia. J. Clin. Psychiatry (2003) 64:605-608.
98. LUND BC, PERRY PJ, BROOKS JM, ARNDT S: Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Arch. Gen. Psychiatry (2001) 58:1772-1776.
99. WANG PS, GLYNN RJ, GANZ DA, SCHNEEWEISS S, LEVIN R, AVORN J: Clozapine use and risk of diabetes mellitus. J. Clin. Psychopharmacol. (2002) 22:236-243.
100. LEONARD P, HALLEY A, BROWNE S: Prevalence of obesity, lipid and glucose abnormalities in outpatients prescribed clozapine. Irish Med. J. (2002) 95:119-120.
101. KINON B, BASSON B, GILMORE JA, TOLLEFSON GD: Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J. Clin. Psychiatry (2001) 62:92-100.
102. CASEY D: Weight gain and glucose metabolism with atypical antipsychotics. 38th Annual Meeting Am. Cool. Neuropsychopharmacol. Acapulco, December (1999).
103. MELKERSSON KI, HULTING AL, BRISMAR KE: Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J. Clin. Psychiatry (2000) 61:742-749.
104. LINDENMAYER J-P, SMITH RC, SINGH A, PARBER B, CHOUE J, KOTSAFITS A: Hyperglycemia in patients with schizophrenia who are treated with olanzapine [letter]. J. Clin. Psychopharmacol. (2001) 21 351-353.
105. BISWAS PN, WILTON LV, PEARCE GL, FREEMANTLE S, SHAKIR SA: The pharmacovigilance of olanzapine: results of a post-marketing surveillance study on 8858 patients in England. J. Psychopharmacol. (2001) 15 265-271.
106. RENSTEIN MJ, SIROTOVSKAYA LA, JONES LE, MOHAN S, CHASANOV MA: Effect of clozapine-quetiapine combination therapy on weight and glycaemic control: preliminary findings. Clin. Drug Invest. (1999) 18:99-104.
107. MELKERSSON KI, HULTING AL: Insulin and leptin levels in patients with schizophrenia or related psychoses: a comparison between different antipsychotic agents. Psychopharmacology (2001) 154 205-212.
108. NEWCOMER JW, HAUPT DW, FUCETOLA R et al.: Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch. Gen. Psychiatry (2002) 59:337-345.
109. SERNYAK MJ, LESLIE L, ALARCON RD, LOSONCZY MS, ROSENHECK R: Association of diabetes mellitus with use of atypical neuroleptics in treatment of schizophrenia. Am. J. Psychiatry (2002) 159 561-566.
110. MEYER JM: A retrospective comparison of weight, lipid and glucose changes between risperidone and olanzapine-treated inpatients: metabolic outcome after 1 year J. Clin. Psychiatry (2002) 63 425-433.
111. KORO CE, FEDDER DO, L'ITALIEN GJ, WEISS SS, MAGDER LS, KREYENBUHL S: Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. Br. Med. J. (2002) 325:243-248.
112. GIANFRANCESCO FD, GROGG AL, MAHMOUD RA, WANG R, NASRALLAH HA: Differential effects of risperidone, olanzapine, clozapine and conventional antipsychotics on Type 2 diabetes: findings from a large health plan database. J. Clin. Psychiatry (2002) 63:920-930.
113. BUSE JB, CAVAZONNI P, HOMBUCKLE K, HUTCHINS D, BRIER A, JAVONOVIC L: A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J. Clin. Epidemiol. (2003) 56:164-170.
114. WIRSHING DA, BOYD JA, MENG LR, BALLON JS, MARDER SR, WIRSHING WC: The effects of novel antipsychotics on glucose and lipid levels. J. Clin. Psychiatry (2002) 63:856-865.
115. HEDENMALM K, HAGG S, STAHL M, MORTIMER O, SPIGSET O: Glucose intolerance with atypical antipsychotics. Drug Saf. (2002) 25 15):1107-1116.
116. SOWELL MO, MUKHOPADHYAY N, CAVAZZONI P et al.: Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. J. Clin. Endocrinol. Metab. (2002) 87:2918-2923.
117. BREIER A: Risk factors for diabetes mellitus during antipsychotic treatment. Int. J. Neuropsychopharmacology (2004) 1(Suppl.):SP25.03.
118. CARO JJ, WARD A, LEVINTON C, ROBINSON K: The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J. Clin. Psychiatry (2002) 63:1135-1139.
119. LINDENMAYER JP, CZOBOR P, VOLAVKA J et al.: Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am. J. Psychiatry (2003) 160(2):290-296.
120. FULLER FA, SHERMOCK KM, GROGG AL: Comparative study of the development of diabetes mellitus in patients taking risperidone, and olanzapine. Pharmacotherapy (2003) 23:1037-1043.
121. KABINOFF GS, TOALSON PA, HEALEY KM, MCGUIRE HC, HAY DP: Metabolic issues with atypical antipsychotics in primary care: dispelling the myths. J. Clin. Psychiatry (2003) 5:6-14.
122. KORNEGAY CJ, VASILAKIS-SCARAMOZZA C, JICK H: Incident diabetes associated with antipsychotic use in the United Kingdom gmeral practice research database. J. Clin. Psychiatry (2002) 63 758-762.
123. CUNNIGHAM C, LAMBERT B, DALACK G et al.: Diabetes associated with antipsychotic use in Veterans with schizophrenia. Psychoepidemiol. Drug. Saf. (2003) 12(Suppl. 1):5154-5155.
124. ALLISON DB, MENTORE JL, MOON SEONG H: Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry (1999) 156:1686-1696.
125. TAYLOR DM, MCASKILL R: Atypical antipsychotics and weight gain - a systematic review. Acta Psychiatr. Scand. (2000) 101 416-432.
126. BRUGHA TS, WING JK, SMITH BL: Physical health of long-term mentally ill in the community: is there unmet need? Br. J. Psychiatry (1989) 155:777-781.
127. KENDRICK T: Cardiovascular and respiratory risk factors and symptoms among general practice patients with long-term mental illness. Br. J. Psychiatry (1996) 169: 733-739.
128. ALLISON DB, MENTORE JL, HERO M et al.: Antipsychotic induced weight gain: a comprehensive synthesis. Am. J. Psychiatry (1999) 156:1686-1696.
129. RYAN MC, THAKORE JH: Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci. (2002) 71 239-257.
130. THAKORE JH: Metabolic disturbance in first- episode schizophrenia. Br. J. Psychiatry (2004) 184(Suppl. 47):S102-S105.
131. PEDERSON SB, JONIER M, RICHELSEN B: Characteristics of regional and gender differences in glucocorticoid receptors and lipoprotein lipase activity in human adipose tissue. J. Clin. Endocrinol. Metab. (1994) 78:1354-1359.
132. HAUPT DW, NEWCOMER JW: Hyperglycemia and antipsychotic medications. J. Clin. Psychiatry (2001) 62:15-36.
133. MEDUNA LJ, GERTY FJ, URSE VG: Biochemical disturbances in mental disorders. Arch. Neurol. Psychiatry (1942) 47:38-52.
134. HOLDEN RJ, PAUKULA IS: The link between diabetes and schizophrenia an immunological explanation. Aust. NZ. J. Psychiatry (1999) 33:286-287
135. NEWCOMER JW, HAUPT DW, FUCETOLA R et al.: Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch. Gen. Psychiatry (2002) 39:337-345.
136. DWYER DS, LIU Y, BRADLEY RJ: Dopamine receptor antagonists modulate glucose uptake in rat pheochromocytoma cells. Neurosci. Lett. (1999) 274:151-154.
137. WALTERS JM, WARD GM, BARTON J et al.: The effect of norepinephrine on insulin secretion and glucose effectiveness in noninsulin dependent diabetes. Metabolism (1997) 46 1448-1453.
138. REAVEN GM, LITHELL H, LANDSBERG L: Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N. Engl. J. Med. (1996) 334 374-381.
139. LIN REAVEN GM: Syndrome X: 6 years later. J. Intern. Med. (1994) 236:13-22.
140. DAGAGO-JACK S, SANTIAGO JV: Pathophysiology of Type 2 diabetes and modes of action of therapeutic interventions. Arch. Intern. Med. (1997) 157:1802-1817.
141. YAZICI KM, ERBAS T, YAZICI AH: The effect of clozapine on glucose metabolism. Exp. Clin. Endocrinol. Diabetes (1998) 106 475-477.
142. GHAELI P, DUFRESNE RL: Serum triglycerides in patients treated with clozapine. Am. J. Health Sys. Pharm. (1996) 53 2709-2081.
143. OSSER DN, NAJARIAN DM, DUFRESNE RL: Olanzapine increases weight and serum triglyceride levels. J. Clin. Psychiatry (1999) 60:767-770.
144. GHAELI P, DUFRESNE RL: Elevated serum triglycerides on clozapine, resolve with risperidone. Pharmacotherapy (1995) 15 382.
145. SPIVAK B, ROITMAN S, VERED Y et al.: Diminished suicidal and aggressive behavior high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine. Clin. Neuropharmacol. (1998) 21:245-250.
146. SPIVAK B, LAMSCHTEIN C, TALMON Y et al.: The inpact of clozapine treatment on serum lipids in chronic schizophrenic patients. Clin. Neuropharmacol. (1999) 22:98-101.
147. MITTELMAN SD, BERGMAN RN: Inhibition of lipolysis causes suppression of endogenous glucose production independent of changes in insulin. Am. J. Physiol. Endocrinol. Metab. (2000) 279 E630-E637.
148. NO AUTHORS LISTED: Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. J. Clin. Psychiatry (2004) 65:267-272.